KR101641902B1 - Composition for releasing stress - Google Patents
Composition for releasing stress Download PDFInfo
- Publication number
- KR101641902B1 KR101641902B1 KR1020150089789A KR20150089789A KR101641902B1 KR 101641902 B1 KR101641902 B1 KR 101641902B1 KR 1020150089789 A KR1020150089789 A KR 1020150089789A KR 20150089789 A KR20150089789 A KR 20150089789A KR 101641902 B1 KR101641902 B1 KR 101641902B1
- Authority
- KR
- South Korea
- Prior art keywords
- stress
- test
- extract
- broccoli
- experimental group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 54
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 38
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 38
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 230000003340 mental effect Effects 0.000 claims description 4
- 244000308180 Brassica oleracea var. italica Species 0.000 claims description 3
- 206010033864 Paranoia Diseases 0.000 claims description 3
- 208000027099 Paranoid disease Diseases 0.000 claims description 3
- 206010024264 Lethargy Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 29
- 239000013642 negative control Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000036506 anxiety Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012346 open field test Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000011302 passive avoidance test Methods 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010020400 Hostility Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010042209 Stress Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- -1 fluoroalkane Chemical compound 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013285 stress animal model Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Images
Classifications
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a food composition comprising an annual roots and a broccoli complex extract as an active ingredient.
As a result, stress can be alleviated, symptoms (diseases) caused by stress can be prevented, or improvements can be made efficiently without side effects.
Description
The present invention relates to a composition for relieving stress, and more particularly, to a composition containing a one-year-old roast and broccoli extract as an active ingredient to alleviate stress and prevent and improve symptoms caused by stress.
The stress, called the source of the vampires, is in every area of human or animal life. Stress is a powerful stimulus that is triggered by a variety of factors, from minor things experienced in daily life to major events giving a great impact. Such stimuli stimulate fatigue, fatigue, depression, and negative reactions both internally and externally Cause.
In recent years, various methods have been proposed to relieve stress. Exercise and psychotherapy have been used most effectively. In addition, there are methods to minimize the damage caused by stress due to the concurrent medication depending on the intensity of the stress. In particular, benzodiazepines (Patent Document 1), which is a nervous stabilizer, and fragrance drugs such as a tranquilizer, which is a psychostabilizer, are used as drugs for relieving stress.
However, there is a risk of poisoning when using such a stabilizer for stress relief, and it is difficult to exclude side effects due to the nature of synthetic drugs. Negative aspects exist because excessive dependence on drugs can cause another stress.
Meanwhile, the present inventors have found that a one-year-old rod and a broccoli combination extract effectively relieve stress and have an effect on symptoms (diseases) caused by stress during searching for a natural medicine effective for relieving stress which can replace synthetic drugs , Thereby completing the present invention.
Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made in order to solve the above-mentioned problems, and an object of the present invention is to provide a method for treating stress, comprising an annual extract and a broccoli extract, And to provide a composition for mitigation.
In order to solve the above-mentioned problems, the composition according to the present invention is characterized by containing a one-year rod and broccoli complex extract as an active ingredient.
The composition for alleviating stress which contains the one-year-old roast and broccoli extract as an active ingredient according to the present invention can relieve stress using natural medicines and can prevent symptoms (diseases) caused by stress or can be efficiently improved without side effects have.
1 is a graph showing the number of times the test animal crosses the open field in the open field test
2 is a graph showing the number of times the test animal searches for the surroundings in the open field test
3 is a graph showing the immobility time of the test animal in the forced swimming test
4 is a graph showing the immobility time of the test animal in the tail suspension test
5 is a graph showing the movement delay time of the test animal in the passive avoidance test
Fig. 6 is a graph showing the relative increase of TNF-a in test animals
Figure 7 is a graph showing the relative increase in IL-6 in test animals
Before describing the present invention, the meaning of terms used in the present invention will be described.
In the present specification, 'extract' means to be used as a crude extract in the art, but broadly also includes the meaning of fractions in which the extract is further fractionated. That is, one year roots and broccoli extracts are obtained not only by using the above-mentioned extraction solvent but also by additionally applying a purification process thereto. For example, the extract may be fractionated by passing it through an ultrafiltration membrane having a constant molecular weight cut-off value, or by separation by various chromatographies (prepared for separation by size, charge, hydrophobicity or affinity) Fractions obtained through various purification methods are also included in the one-year roots and broccoli extracts of the present invention.
As used herein, the term " comprising as an active ingredient " means an amount sufficient to achieve the efficacy or activity of the annual roots and broccoli extract. The present invention relates to a composition extracted from a natural plant material such as broccoli and an annual roots, and even if administered in an excessive amount, there is no adverse effect on the human body. Therefore, the quantitative upper limit of the composition containing the roots and broccoli extracts of one year can be appropriately selected .
As used herein, a "pharmaceutically effective amount" means an amount sufficient to achieve efficacy or activity of an annual roots and broccoli extract.
The one-year-old roots and broccoli extracts of the present invention are extracted using an organic solvent. The following extracts can be used as the extraction solvent.
(I) water, (ii) an alcohol having 1 to 6 carbon atoms (preferably, methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, , 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) DMFO (Dimethyl-formamide) and (v) DMSO (dimethyl sulfoxide).
Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1 Chlorophenyl, 1-chlorobutane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, chloroform, Dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, methylene chloride, petroleum ether and THF.
(B) a water-soluble or lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol and water, (d) ), Acetone, ethyl acetate, chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether, For easy extraction, it is more preferable to extract water, ethanol or a mixture of water and ethanol by treatment with broccoli and one year rods.
In addition, the annual roots and broccoli extracts used in the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.
Accordingly, the present invention can produce an extract using the above-mentioned extraction solvent. Hereinafter, a method of producing a one-year rod and broccoli complex extract will be described.
One year stick
And broccoli complex extract
The roots are screened and pulverized for one year, and then pulverized water is added in an amount of 8 times by volume (w / v) and heated at 80 ° C for 6 hours. The extract is filtered, concentrated in vacuo, mixed with dextrin, and then dried with hot air or lyophilized to obtain the final extract.
Broccoli leaves are selected and pulverized, and then water is extracted twice at a temperature of 70 ° C for 4 hours by adding 5 times by volume of pulverized water (w / v). The extract is filtered, concentrated in vacuo, mixed with dextrin, and then dried with hot air or lyophilized to obtain the final extract.
One year roots extract and broccoli extract are mixed at a ratio of 2: 8 to 8: 2 to prepare a one-year rod and broccoli complex extract. One year roots and broccoli complex extracts to be used in the animal tests below were prepared by mixing 1: 2 bar extract and broccoli extract with 2: 8 and 8: 2, respectively. Extracts are mixed at a ratio of 5: 5.
Hereinafter, it is examined whether or not the one-year-old roast and broccoli combination extract according to the present invention is effective for relieving stress. For this purpose, a stress animal model was used in each test.
Animal test
1) Test subjects
After 4 weeks of ICR male mice (Samtaco Bio Korea, Inc.), the lights were turned on and off repeatedly every 12 hours after the adaptation period of one week, and the room temperature was maintained at 18 to 23 ° C and the humidity was maintained at 60% . The feeds were fed solid feed and there were no restrictions on feeding and watering except in the process of inducing stress.
And 5 mice were classified into the normal control group, the negative control group, the first experimental group, the second experimental group, the third experimental group and the fourth experimental group, respectively. In the second experiment, broccoli extract was used. In the third experiment group, 2: 8 mixed one-year roots and broccoli mixed extracts were used. In the fourth experiment group, 8 : 2 and a broccoli combination extract were orally administered (40 mg / kg) between 14 and 15 hours daily for 5 weeks.
2) Stress induction
The negative control, the first experimental group, the second experimental group, the third experimental group and the fourth experimental group of the test subjects were induced to stress for 7 days from the 7th day of the physiological saline or extract administration for 4 weeks. The stress-inducing method is modified by the method of Willner et al. (Wilner et al., Reduction of sucrose preference by chronic unpredictable mild stress, 1987). Specifically, fasting, dietary restriction after fasting , Creating an unexpected variety of mental stress situations such as providing an empty water bottle after the singularity, leaning a kennel, breeding a large number of laboratory animals in a kennel, flashing lights, cold rooms, and constant light.
Test Example
1: Exercise ability and behavior observation test
1) Open Field Test
The open field test was performed on the normal control group, the stress-induced negative control group, the first experimental group, the second experimental group, the third experimental group and the fourth experimental group (hereinafter referred to as "test animals"). The open field test is carried out in a black acrylic box (40 × 60 × 50 cm) with an open ceiling and a slope. The bottom of the acrylic box was divided into 12 equal-sized squares. The animals were placed in a box for 2 minutes of adaptation time, and the number of times that the animal crossed the open field for 3 minutes and Rearrange the number of times you are standing up with your forefoot. The results are shown in FIGS. 1 and 2, respectively.
Results were expressed as mean and standard error, and significance was verified by statistical treatment using Student's t-test, and compared with stress-control (Stress-CTL) 0.05 vs. Stress-CTL).
As shown in FIG. 1 and FIG. 2, it can be seen that the stress-induced negative control significantly decreased the movement in the open field as compared with the normal control group. In general, when stress is induced, anxiety increases, activity decreases in the open field, and behavior in the corner increases. This is supported by the negative control group. On the other hand, the first experimental group treated with barley extract for one year showed a 40% higher frequency of moving across the open field or searching for the surrounding area with the forepaw compared to the negative control group. However, in the second experimental group, 90% of the negative control group showed no significant results. However, in the third experimental group treated with the roots and broccoli complex extracts, the frequency of movement across the open field or the forehead was 1.5 times higher than in the negative control group, and more than 2 times higher in the fourth experiment group. Therefore, one year 's bar extract can reduce the anxiety caused by stress in itself, and the effect is better when used with Broccoli extract.
2) Forced Swimming Test
A forced swimming test was performed on test animals. Fill the cylindrical transparent water tank (diameter 14 cm,
Results were expressed as mean and standard error, and significance was verified by statistical treatment using Student's t-test, and compared with stress-control (Stress-CTL) 0.05 vs. Stress-CTL). The result is shown in Fig.
As shown in FIG. 3, the negative control group has a longer floating time than the normal control group. In contrast, in the first experimental group, the immobility time was longer than that of the normal control group, but the immobilization time was shorter than that of the negative control group by 70%. On the other hand, the second experimental group showed no significant difference in the comparison with the negative control group, but the third experimental group and the fourth experimental group, in which the one-year-old rod and broccoli complex extract were administered, Able to know. Therefore, it can be seen that the complex extract is more effective for the dwelling time reduction than the single-rod or broccoli alone extract.
3) Tail Suspension Test
The tail suspension test was repeated two times. The test animal is held at a height of 15 cm from the bottom and 1 cm end of the tail is held for 6 minutes to observe the movement of the test animal. The initial 2 minutes is considered as the adaptation period and the time when the animal does not move for 4 minutes before the end is measured and recorded.
Results were expressed as mean and standard error, and significance was verified by statistical treatment using Student's t-test, and compared with stress-control (Stress-CTL) 0.05 vs. Stress-CTL). The result is shown in Fig.
As shown in FIG. 4, it can be seen that the negative control group is immersed in the tail and the immersion time in the inverted state is longer than that of the normal control group. This means that the immobility time is increased due to the mental stress and the frustration is increased. In the first experimental group, the immobility time was short of 75% and the body was relatively moved compared with the negative control group. However, the second experimental group showed a result of 90% floating time compared to the negative control group. On the other hand, in the 3rd experimental group and the 4th experimental group, the immobility time was lowered to 60% of the negative control group. Thus, it can be seen that the one year roots and broccoli complex extract are more effective in relieving the lethargy and frustration caused by stress.
Test Example
2: Memory test
1) One-Trial Passive Avoidance Test
Passive avoidance test was performed on test animals. The passive avoidance test was conducted on the 4th week after administration of physiological saline or one-year rod and broccoli combination extract (on the 29th day of the extract administration) ) And one retention trial after 24 hours of electric shock. Specifically, a passive evasion test instrument is required to perform the passive evasion test. The passive evasion test instrument is divided into two sections, which are movable through the middle door, and the bottom is made of a wire mesh. In addition, the training was carried out by placing the test animal in a passive evasion test apparatus and then injecting light and noise into one area where the test animal is located with a 90 second adaptation period in the dark, It moves in a way that avoids light and noise by moving. And through this training, when the test animal moved to the dark area, a current of 1.0 mA caused a foot shock to flow for 2 seconds.
After 24 hours of such training and electrical shock, the test animals are placed in the first zone and stimulated for 90 seconds with light and noise. The time taken for the test animals to move through the door to the dark area was measured. The maximum measurement time was 300 seconds
Results were expressed as mean and standard error, and significance was verified by statistical treatment using Student's t-test, and compared with stress-control (Stress-CTL) 0.05 vs. Stress-CTL). The result is shown in Fig.
As shown in FIG. 5, there was almost no difference in the moving time of the test animals in the acquisition test as the initial training course. On the other hand, there was a difference in the memory test, and the time taken for the normal control to move to the dark area was measured close to 300 seconds. This means that memory for the perceived footshock in the acquisition test limits movement to dark areas. The negative control group had a very short time to move to the dark area of 30 seconds, because the footshock in the acquisition test was not memorized for a long time due to memory loss due to stress. On the other hand, in the first experiment group, the time taken to move to the dark zone was 120 seconds, which was much longer than the negative control group. In the second experiment group, the time taken to move to the dark zone was about 40 seconds, which was almost the same as the negative control group. In the third experimental group and the fourth experimental group, the time required to move to the dark area was 190 seconds, which was significantly different from the negative control, and the results were also different from those of the first experimental group and the second experimental group. Thus, it can be seen that the one-year-old roast and broccoli combination extract according to the present invention is more effective in preventing the memory loss due to stress than the single extract.
Test Example
3: Inflammatory cytokine measurement
For the measurement of inflammatory cytokines, the test animals in which the tests of Test Example 2 and Test Example 3 have been completed are sacrificed by cervical dislocation, the brains are harvested, and the hippocampus tissue is cut and cooled rapidly in a coldly-cooled tube. Each tissue sample was treated with 0.4 M perchloric acid, sonicated, centrifuged at 12,000 rpm / 20 min in a centrifuge, and supernatant was used for analysis. The amounts of inflammatory cytokines TNF-a and IL-6 were measured by ELISA Kit according to the manufacturer's method.
The results were expressed as mean and standard error by comparing the cytokine measurements of the negative control, the first experimental group, the second experimental group, the third experimental group and the fourth experimental group based on the cytokine measurement values of the normal control group. Statistical analysis using Student's t-test was used to signify significance at p <0.05 compared to negative control (* p <0.05 vs. Stress-CTL). The results are shown in Fig. 6 and Fig.
As a result of the test, as shown in FIG. 6 and FIG. 7, it can be seen that the amount of TNF-α and IL-6 was significantly higher in the negative control group than in the normal control group due to the stress. In the first experimental group, TNF-α and IL-6 were found to be -20% lower than the negative control group, but the second experimental group showed no significant difference compared to the negative control group. On the other hand, in the third experimental group and the fourth experimental group, TNF-α was measured as low as 60 to 65%, and IL-6 was measured as low as 50% as compared with the negative control. Thus, it can be seen that the one-year-old roots and the broccoli combination extract according to the present invention are more effective in relieving the increase of inflammatory cytokines due to stress than the individual extracts.
Clinical trial
1) Test subjects
Adult male and female adults aged 19 years and over were randomly divided into 20 control and experimental groups. In the experimental group, a capsule containing 500 mg of a rod extract and a broccoli complex extract was taken per day for 30 days, and the control group was given the same placebo capsule as the capsule. After 30 days of ingestion, the same stress symptom improvement test as before ingestion was performed.
Test Example
4: Stress symptom improvement test
(Symtom Checklist-Revised: SCL-90-R) was administered to the control and experimental groups. The simple psychiatric test was developed by Derogatis (997), and Kim, Kwang - il et al. (1984) was used in Korean for evaluation of physical and mental symptoms due to stress. This test has 90 items and each item is classified into nine sub - dimensions such as somatization, obsessive - compulsive, interpersonal sensitivity, depression, anxiety, hostility, fear anxiety, paranoia, psychiatric scale. Depending on the severity of the symptoms, use a 5-point scale from "no (0)" to "very severe (4)".
The results were expressed as mean symptom improvement ratio by comparing scores before and after ingestion of 9 sub - dimensions. The results are shown in Table 1.
As a result of the test, as shown in Table 1, the experimental group showed improvement in symptoms due to stress. Hostility improvement showed the highest improvement rate of 75%, and somatization, depression, anxiety, fear anxiety, , And the rate of improvement is low even in other obsessive-compulsive disorder, interpersonal sensitivity, paranoia, and the like. On the other hand, the control group had a poor improvement rate of symptoms due to stress between 4% and 9%, and the sensitivity to interpersonal affects also deteriorated. Thus, it can be seen that the one-year-old roast and broccoli combination extract according to the present invention is effective in relieving various symptoms and diseases caused by stress.
Claims (3)
Broccoli leaves were pulverized, and then water of 5 times by volume (w / v) of pulverized water was added, and the mixture was subjected to hot-water extraction at 70 ° C for 4 hours. The mixture was extracted twice and then dried to prepare a mixture of broccoli extract , Depression, lethargy, obsessive compulsive disorder, anxiety disorder, paranoia, and stress inflammation due to mental stress comprising as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150089789A KR101641902B1 (en) | 2015-06-24 | 2015-06-24 | Composition for releasing stress |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150089789A KR101641902B1 (en) | 2015-06-24 | 2015-06-24 | Composition for releasing stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101641902B1 true KR101641902B1 (en) | 2016-07-22 |
Family
ID=56681466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150089789A KR101641902B1 (en) | 2015-06-24 | 2015-06-24 | Composition for releasing stress |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101641902B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200144763A (en) * | 2019-06-19 | 2020-12-30 | 대한민국(농촌진흥청장) | Composition comprising Erigeron annuus (L.) Pers. for preventing or treating of Degenerative Brain Diseases |
| KR20210118492A (en) * | 2020-03-23 | 2021-10-01 | 주식회사 네이처센스 | A composition for improving memory, cognitive function, or preventing and improving brain neurological diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100195566B1 (en) | 1990-04-25 | 1999-06-15 | 테렌스 로저 | Pharmaceutical compounds |
| JP2009126826A (en) * | 2007-11-22 | 2009-06-11 | Atsuo Sekiyama | Anti-stress agent |
| CN103705780A (en) * | 2014-01-02 | 2014-04-09 | 王秋玲 | Medicament for treating intractable insomnia |
-
2015
- 2015-06-24 KR KR1020150089789A patent/KR101641902B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100195566B1 (en) | 1990-04-25 | 1999-06-15 | 테렌스 로저 | Pharmaceutical compounds |
| JP2009126826A (en) * | 2007-11-22 | 2009-06-11 | Atsuo Sekiyama | Anti-stress agent |
| CN103705780A (en) * | 2014-01-02 | 2014-04-09 | 王秋玲 | Medicament for treating intractable insomnia |
Non-Patent Citations (1)
| Title |
|---|
| Jo Mi Jeong 외 4명, ‘Roots of Erigeron annuus Attenuate Acute Inflammation as Mediated with the Inhibition of NF-κB-Associated Nitric Oxide and Prostaglandin E2 production’, Evidence-Based Complementary and Alternative Medicine 제2013권, Article ID 297427, 2013년. * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200144763A (en) * | 2019-06-19 | 2020-12-30 | 대한민국(농촌진흥청장) | Composition comprising Erigeron annuus (L.) Pers. for preventing or treating of Degenerative Brain Diseases |
| KR102366476B1 (en) | 2019-06-19 | 2022-02-23 | 대한민국 | Composition comprising Erigeron annuus (L.) Pers. for preventing or treating of Degenerative Brain Diseases |
| KR20210118492A (en) * | 2020-03-23 | 2021-10-01 | 주식회사 네이처센스 | A composition for improving memory, cognitive function, or preventing and improving brain neurological diseases |
| KR102402315B1 (en) | 2020-03-23 | 2022-05-26 | 주식회사 네이처센스 | A composition for improving memory, cognitive function, or preventing and improving brain neurological diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Schisantherin A recovers Aβ-induced neurodegeneration with cognitive decline in mice | |
| Ahmadi et al. | Effects of vanillic acid on Aβ1-40-induced oxidative stress and learning and memory deficit in male rats | |
| Tag et al. | Potential anti-inflammatory effect of lemon and hot pepper extracts on adjuvant-induced arthritis in mice | |
| Kumar et al. | Fostered antiarthritic upshot of moringa oleifera lam. stem bark extract in diversely induced arthritis in wistar rats with plausible mechanism | |
| KR20160044807A (en) | Composition comprising extracts or fractions of Justicia genus | |
| KR101641902B1 (en) | Composition for releasing stress | |
| KR101492688B1 (en) | Pharmaceutical composition comprising mixed extracts of paeonia lactiflora pallas and dried rhizomes of zingiber officinale roscoe for preventing or treating of dementia and cognitive dysfunction | |
| CN107920974A (en) | The cosmetic composition for being used to suppress pruritus and improvement atopic dermatitis containing active ingredient ISTP | |
| KR20190087343A (en) | Composition for ameliorating skin disorder comprising Artemisia annua extracts and method for preparation thereof | |
| Lee et al. | Inhibitory effect of phytoglycoprotein (24ákDa) on allergy-related factors in compound 48/80-induced mast cells in vivo and in vitro | |
| JP6638161B2 (en) | Food and beverage composition for inhibiting fat accumulation, food and beverage composition for preventing or treating fatty liver, and food and beverage composition for inhibiting fatty acid synthase | |
| Sahebari et al. | Inhibitory effect of aqueous extract of saffron (Crocus sativus L.) on adjuvant-induced arthritis in wistar rat | |
| KR102089490B1 (en) | Composition for improving memory or composition for preventing and treating Alzheimer's dementia containing boiled silkworm products having silk protein and angelica extracts | |
| CN102727484A (en) | Use of silymarin in preparations of drugs for treatment of Alzheimer's disease | |
| KR20160131351A (en) | A composition containing hippocampus abdominalis extract for improving ability of memory | |
| KR101623385B1 (en) | Composition for memory, cognition, or learning abilities | |
| CN108434358B (en) | Nutritional composition with neuroprotective effect and preparation method and application thereof | |
| KR102096346B1 (en) | Compostion for preventing or treating the Developmental Disability comprising Humulus japonicus extract as active ingredient | |
| KR101316095B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb１ and Rg３，Compound K，or saponin extract from Panax ginseng as an effective ingredient | |
| CN105456114A (en) | Whitening cosmetic containing Rhodiola rosea extract, polygonum multiflorum extract and ganoderma extract | |
| KR101887585B1 (en) | A composition for preventing or treating the cognitive dysfunction or neuroinflammation comprising Ambrosia artemisiifolia extract or a fraction thereof as active ingredient | |
| KR20190133457A (en) | Composition for improving memory or composition for preventing and treating Alzheimer's dementia containing boiled silkworm products having silk protein | |
| CN112826838B (en) | Application of kohlrabi or extract thereof | |
| CN110787196B (en) | Application of cassytha tenuifolia and extract thereof in preparation of drugs for treating and/or preventing alcoholic liver injury | |
| KR102499814B1 (en) | Composition comprising Pteridium aquilinum var. latiusculum extract for preventing or treating neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190717 Year of fee payment: 4 |